In 2023, Genomic Health settled with DOJ for $32M re 14 day rule activities. No admission of wrongdoing was made.
Here are some links including the 18 page settlement. Then, I give an AI summary.
DOJ Press
Phillips Cohen
https://www.phillipsandcohen.com/genomic-health-pays-32-5m-to-settle-medicare/
Tycko
Wolters
https://www.vitallaw.com/news/false-claims-act-settlement-agreements-genomic-health-to-pay-32-5-million-to-settle-allegations-relating-to-cancer-screening-tests/hld01b25281a1a6834863b5690562a6de430fThe Department of Justice settlement with Genomic Health, Inc. is an unusually clear window into how Medicare billing rules, clinical workflows, and financial pressures can collide—and how that collision can be reinterpreted, in hindsight, as fraud. For a small hospital performing lung cancer surgeries, the case is not abstract. It maps directly onto a daily operational dilemma: how to obtain high-value genomic results for clinicians when the hospital cannot absorb a $4,000 test within a bundled payment, and yet cannot safely manipulate timing or billing without legal exposure.
At the center of the case is Medicare’s “14-day rule,” also known as the Date of Service (DOS) rule. Under this framework, molecular tests ordered within 14 days of a hospital discharge—whether inpatient or outpatient—are considered part of the hospital service. For inpatients, the cost is bundled into the Diagnosis-Related Group (DRG) payment. For outpatients, the hospital is financially responsible, even if it may later seek reimbursement. Only when the test is performed more than 14 days after discharge may the laboratory bill Medicare directly. This creates a stark discontinuity: a test performed on day 13 is the hospital’s financial burden; the same test on day 15 is billable by the lab to Medicare. The Genomic Health case is, in essence, about what happens when organizations attempt to navigate—or exploit—that discontinuity.
According to the settlement agreement and DOJ press materials, the government alleged that Genomic Health engaged in a coordinated, multi-year strategy to circumvent the 14-day rule, spanning roughly 2007 to 2020 (Settlement Agreement, Sept. 12, 2023, Recitals D; DOJ Press Release, Oct. 2, 2023). The allegations were not limited to isolated billing errors but described a systematic pattern of behavior. First, the company allegedly delayed or held test orders that had been placed within the 14-day window, so that the eventual date of service would fall outside the window and permit direct Medicare billing. The settlement explicitly states that Genomic Health “cancelled, delayed, held or otherwise did not process orders” in order to shift the billing outcome (Settlement Agreement, Recitals D(1)). Second, the company allegedly participated in or encouraged “cancel-and-reorder” behavior, whereby tests initially ordered within 14 days of discharge were cancelled and then reordered after the window elapsed. Importantly, DOJ emphasized not only active encouragement but also the “failure to discourage” such behavior (Settlement Agreement, Recitals D(2), D(4)).
Third, DOJ alleged that the company sometimes billed Medicare directly for tests that were clearly within the prohibited 14-day window, particularly in the outpatient setting, constituting straightforward violations of the rule (Settlement Agreement, Recitals D(3)). Fourth, the same cancel-and-reorder pattern was alleged in outpatient contexts as in inpatient ones, reinforcing the view of a systemic approach rather than isolated events. Finally, and perhaps most legally consequential, DOJ alleged that Genomic Health failed to bill hospitals for tests that should have been their financial responsibility, instead writing off those charges. This was characterized as remuneration to induce referrals, triggering the Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) and, by extension, False Claims Act liability (Settlement Agreement, Recitals D(5)).
The financial resolution reflects the seriousness of these allegations: Genomic Health agreed to pay $32.5 million, with $16.25 million designated as restitution, and whistleblowers received approximately $5.7 million (DOJ Press Release, Oct. 2, 2023; Settlement Agreement, ¶¶1–2). While the settlement formally disclaims admission of liability, the factual narrative constructed by DOJ is unmistakable. The government repeatedly framed the conduct not merely as regulatory noncompliance but as behavior that “delayed tests for cancer patients for no reason other than to circumvent a Medicare requirement,” thereby prioritizing financial outcomes over patient care (DOJ Press Release, Oct. 2, 2023).
What transforms this case from a technical billing dispute into a fraud case are three interlocking elements: intent, pattern, and inducement. First, intent was inferred from the systematic nature of the conduct—repeated delays, consistent timing shifts, and coordinated interactions with providers. Second, the pattern extended over more than a decade, suggesting that the behavior was embedded in operational processes rather than arising from occasional ambiguity. Third, and critically, the alleged financial concessions—specifically the failure to collect payment from hospitals—introduced an Anti-Kickback dimension that independently supports liability. Even if the timing issues had been ambiguous, the provision of free or discounted services tied to referral patterns would raise substantial legal risk.
For a small hospital performing lung cancer surgeries, the implications are both immediate and sobering. The hospital faces a real economic constraint: genomic tests are expensive, often exceeding the marginal reimbursement embedded in DRG payments. Yet the Genomic Health case demonstrates that attempts to “solve” this problem through timing manipulation or informal financial arrangements can expose both the laboratory and the hospital to significant liability. Practices that may appear operationally reasonable—delaying a test by a few days, coordinating with a lab to reorder a test, or accepting a waived charge—can, when viewed collectively and retrospectively, be construed as a deliberate scheme to shift payment responsibility.
The safest and most defensible pathway for such a hospital is to align testing decisions with genuine clinical workflow rather than reimbursement considerations. One viable model is to structure genomic testing as part of post-discharge outpatient care, where the decision to order the test is made after discharge based on clinical evaluation, pathology results, or multidisciplinary tumor board discussion. In this scenario, the timing reflects real clinical decision-making rather than financial engineering, and the laboratory may legitimately bill Medicare if the test is performed outside the 14-day window. However, the distinction must be real and well-documented. If the decision to test is effectively made during the inpatient stay and merely deferred for billing reasons, the risk remains.
Equally important are internal controls and documentation. Hospitals must establish clear policies that separate clinical decision-making from financial considerations, prohibit cancel-and-reorder practices, and require documentation of the clinical rationale for the timing of tests. Patterns should be monitored: if nearly all tests cluster just beyond the 14-day threshold, this may invite scrutiny regardless of stated intent. Moreover, hospitals must avoid accepting financial concessions from laboratories that could be construed as remuneration. The Genomic Health case makes clear that even the failure to invoice can be interpreted as an inducement under the Anti-Kickback Statute.
Ultimately, the line between compliant behavior and fraud in this domain is not defined solely by the calendar. It is defined by whether timing reflects legitimate clinical care or is engineered to achieve a particular reimbursement outcome. The Genomic Health settlement illustrates that regulators will look beyond individual transactions to the broader pattern and purpose of conduct. For hospitals, especially smaller institutions operating under financial pressure, the lesson is not that genomic testing is infeasible, but that it must be integrated into care pathways in a manner that is both clinically authentic and rigorously documented. In this environment, compliance is not merely about following rules—it is about being able to demonstrate, convincingly and consistently, that patient care, rather than payment optimization, drives decision-making.
